BCOP Test Bundle - NCCN 2022 Pharmacy Updates: A Webinar Series
In partnership with Hematology/Oncology Pharmacy Association (HOPA), NCCN is pleased to offer board-certified oncology pharmacist (BCOP) recertification education.
One BCOP test will be released each month. Topics can be viewed under the Schedule tab. You can choose to purchase all tests or select individual tests, receiving BCOP credit for each completed test when you achieve a passing score.
Earn up to 12 hours of BCOP Credit!
Each BCOP test may be taken only once. Within the test, you will be able to go back and revisit questions you have already answered. Your test progress will be saved after each question, allowing you to leave the test incomplete and then resume it from where you left off, if needed. You will be required you to click a submit button before your test will be graded.
If you pass a test with a score of 75% or higher, you will be asked to enter your BPS ID and Credential Number. Please be sure to have this information available. If you do not know your BPS ID number, please contact the Board of Pharmacy Specialties.
As part of the review process, qualified BCOP reviewers evaluate all BCOP tests for individual question performance and participant feedback on how well the questions were worded and answerable from the materials provided. If you have any questions or concerns about the BCOP tests, please email firstname.lastname@example.org.
One BCOP test will be released each month and made available for one year.
This page will be updated as test release dates are confirmed:
- January 28, 2022, at 3:00 PM EST - Understanding the Place in Therapy for an Oral LHRH Antagonist as a Treatment Option in Prostate Cancer
- February 25, 2022, at 2:30 PM EST - Not Just a Band-Aid: The Impact of Chemotherapy Dose Banding in Infants
- March 10, 2022, at 1:00 PM EST - Crossroads of Exercise and Chemotherapy
- April 29, 2022, at 1:30 PM EDT - Mycosis Fungoides and Sézary Syndrome: Overview of Systemic Therapy
- May 20, 2022, at 1:00 PM EDT - CAR-T Therapy in Multiple Myeloma
- June 30, 2022, at 12:00 PM EDT - Updates in the Management of Unresectable or Metastatic Cutaneous Melanoma
- August 16, 2022, at 4:00 PM EDT - Navigating Advances in Targeted Therapies for Advanced Esophageal, Esophagogastric Junction (EGJ) and Gastric Cancers
- August 24, 2022, at 2:30 PM EDT - The Role of Tyrosine Kinase Inhibitors in Pediatric Acute Lymphoblastic Leukemia
- October 27, 2022, at 4:30 PM EDT - Novel Therapies for the Treatment of Metastatic Breast Cancer
- November 10, 2022, at 1:00 PM EST - Updates in the Management of Indolent Non-Hodgkin Lymphomas
- November 28, 2022, at 1:00 PM EST - Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer
- January 4, 2023, at 3:00 PM EST - Updates in Older Adult Oncology
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Full disclosure of faculty relationships will be made prior to each activity.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Individual tests are available for a $50 fee. Save $10 per test by purchasing the 12-test bundle!
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing